22280-56-4

Basic information

• Product Name: 2-Chloro-3-methyl-5-nitropyridine
• Synonyms: 2-Chloro-3-methyl-5-nitropyridine,99%;2-Chloro-3-methyl-5-nitropyridine 2-Chloro-5-nitro-3-picoline;TIMTEC-BB SBB003831;BUTTPARK 95\50-52;2-CHLORO-5-NITRO-3-METHYLPYRIDINE;2-CHLORO-5-NITRO-3-PICOLINE;2-CHLORO-3-METHYL-5-NITROPYRIDINE;2-CHLORO-5-NITRO-3-PICOLINE (2-CHLORO-3-METHYL-5-NITROPYRIDINE)
• CAS NO: 22280-56-4
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.57
• EINECS: 244-889-5
• Product Categories: Heterocyclic Building Blocks;Heterocycle-Pyridine series;compounds of pyridine;Pyridine;Pyridines, Pyrimidines, Purines and Pteredines;Pyridine series;Halides;Pyridines;Chloropyridines;Halopyridines;Boronic Acid;Building Blocks;C6;Chemical Synthesis
• Mol File: 22280-56-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 78-80 °C
• Boiling Point: 145 °C / 18mmHg
• Flash Point: >110°C
• Appearance: Light beige to cream/Crystalline Powder
• Density: 1.5610 (rough estimate)
• Vapor Pressure: 0.00504mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• PKA: -3.61±0.10(Predicted)
• Sensitive: Hygroscopic
• CAS DataBase Reference: 2-Chloro-3-methyl-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-methyl-5-nitropyridine(22280-56-4)
• EPA Substance Registry System: 2-Chloro-3-methyl-5-nitropyridine(22280-56-4)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-20/21/22-41-37/38-22
• Safety Statements: 37/39-26-39
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 22280-56-4(Hazardous Substances Data)

Usage

Chemical Properties

Light beige to cream colored crystalline powder

InChI:InChI=1/C6H5ClN2O2/c1-4-2-5(9(10)11)3-8-6(4)7/h2-3H,1H3

Upstream product

• 18344-51-9 2-amino-3-methyl-5-nitropyridine 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 21901-34-8 2-hydroxy-3-methyl-5-nitropyridine 

Downstream Products

• 3430-19-1 5-methylpyridin-3-amine 
• 38186-82-2 6-chloro-5-methylpyridin-3-amine 
• 906463-06-7 2-(2-chloro-phenyl)-3-methyl-5-nitro-pyridine 
• 350-04-9 5-fluoro-3-pyridinecarbonyl chloride 
• 872254-88-1 3-methyl-5-nitro-2-(4-trifluoromethyl-phenyl)-pyridine 
• 19346-46-4 2-fluoro-3-methyl-5-nitropyridine 
• 89694-10-0 2-methoxy-3-methyl-5-nitropyridine 
• 6965-63-5 2-hydrazinyl-3-methyl-5-nitropyridine 
• 1639115-99-3 3,8-dimethyl-6-nitro-[1,2,4]-triazolo[4,3-a]pyridine 

Relevant articles and documents

Computer-aided discovery of aminopyridines as novel JAK2 inhibitors

The Janus kinase 2 (JAK2)-mediated signaling pathway plays an important role in controlling cell survival, proliferation, and differentiation. In recent years, genetic, biological, and physiological evidence has established JAK2 inhibitors as effective chemotherapeutic agents for the treatment of many different cancers. For this reason, we sought to identify novel small molecule inhibitors of JAK2. Using Surflex-Dock software, we tested 3010 compounds with known chemical structures in silico for their ability to interact with the JAK2 ATP-binding pocket. We selected the 10 highest-scoring compounds and tested their abilities to inhibit JAK2 activity in vitro. Compound 1a (ethyl 1-(5-((3-methoxyphenyl)carbamoyl)-3-nitropyridin-2-yl)piperidine-4-carboxylate) was identified. Optimization of 1a using docking studies led to the discovery of compounds 1b and 1d, potent JAK2 inhibitors. Furthermore, as V-shaped kinase inhibitors can curve around the protein backbone and access deep into the pocket, we developed a new series of compounds with a non-linear sulfonamide bond. Nine compounds were prepared and evaluated for JAK2 inhibitory effects. Compounds 7e (IC50 = 6.9 μM) and 7h (IC50 = 12.2 μM) showed better JAK2 inhibition, validating our design approach. This study successfully applied virtual screening for hit discovery, and a docking study for hit optimization. In addition, a novel approach to drug discovery, combining structure- and shape-based drug design, facilitated the design of more potent JAK2 inhibitors. The methods provide a guide for future development of inhibitors targeting JAK2 and other kinases.

Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.

NOVEL MICROBIOCIDES

Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.